Current Pharmacogenomics and Personalized Medicine
Title:Editorial (End of the Beginning and Public Health Pharmacogenomics: Knowledge in ‘Mode 2’ and P5 Medicine)
Volume: 10 Issue: 1
Author(s): Vural Ozdemir, Erik Fisher, Edward S. Dove, Hilary Burton, Galen E. B. Wright, Mario Masellis and Louise Warnich
Affiliation:
Keywords: Africa, global personalized medicine, knowledge in mode 2, omics biotechnologies, P5 medicine, public health pharmacogenomics, science studies, sociomateriality
Export Options
About this article
Cite this article as:
Ozdemir Vural, Fisher Erik, S. Dove Edward, Burton Hilary, E. B. Wright Galen, Masellis Mario and Warnich Louise, Editorial (End of the Beginning and Public Health Pharmacogenomics: Knowledge in ‘Mode 2’ and P5 Medicine), Current Pharmacogenomics and Personalized Medicine 2012; 10 (1) . https://dx.doi.org/10.2174/1875692111201010001
DOI https://dx.doi.org/10.2174/1875692111201010001 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Formulated Squalene for Food Related Applications
Recent Patents on Food, Nutrition & Agriculture Classical Inhibitors of NOX NAD(P)H Oxidases Are Not Specific
Current Drug Metabolism Histopathology of Ductal Carcinoma in Situ (DCIS) of the Breast
Current Cancer Therapy Reviews Cell Culture in Microfluidic Systems
Micro and Nanosystems Technology Whitespaces India Should Focus: A Comparative Anti-Cancer Patent Rational Analysis of Indian and International Public Funded Universities
Recent Patents on Anti-Cancer Drug Discovery Effect of Electromagnetic Radiations on Neurodegenerative Diseases- Technological Revolution as a Curse in Disguise
CNS & Neurological Disorders - Drug Targets Developing FGFR4 Inhibitors As Potential Anti-Cancer Agents Via In Silico Design, Supported by In Vitro and Cell-Based Testing
Current Medicinal Chemistry Ischemic Neuronal Damage
Current Pharmaceutical Design PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer
Current Drug Targets Degludec: A Novel Basal Insulin
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Role of the Adenosinergic Pathway in Immunosuppression Mediated by Human Regulatory T Cells (Treg)
Current Medicinal Chemistry The Effect of Counseling on Stress in Infertile Women Admitted to an Infertility Center in Hamadan City, Iran
Current Psychiatry Research and Reviews RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy Anticancer Studies of Leucovorin against Methotrexate Induced Genotoxicity in Swiss Albino Mice
Letters in Drug Design & Discovery The Influence of Surface Charge on the Antiviral Effect of Curcumin Loaded in Nanocarrier System
Pharmaceutical Nanotechnology Double-Strand Breaks Repair by Non-Homologous DNA End Joining in Mammalian Cells
Current Genomics A Micro-Aggregation Algorithm Based on Density Partition Method for Anonymizing Biomedical Data
Current Bioinformatics Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis?
Current Drug Targets Heterogeneity in the Pathology and Molecular Biology of Breast Cancer
Current Genomics